2021 Year in Review - Gastrointestinal Cancer
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Promising response rates were reported in a clinical trial of neoadjuvant sintilimab with CapeOx in patients with resectable, locally advanced gastric/gastroesophageal junction (GEJ) cancer.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
MAHOGANY Cohort A clinical trial results reveal margetuximab and retifanlimab combination treatment led to tumor response with an acceptable safety profile.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
An early-phase clinical trial of nivolumab with radiotherapy in patients with relapsed unresectable/recurrent gastric cancer demonstrated prolonged patient survival.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Statistically meaningful improvement in progression-free survival, overall survival, and objective response rate was found in patients with advanced gastric cancer treated with bemarituzumab and modified FOLFOX6.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Overall survival and progression-free survival were improved with first-line treatment of camrelizumab with chemotherapy in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC).
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
This edition of Year in Review is focused on gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer, and immunotherapy and targeted therapies used in the management of these cancers.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Results from the KEYNOTE-811 clinical trial indicate pembrolizumab added to trastuzumab plus chemotherapy improves response in HER2-positive gastric or gastroesophageal junction cancer.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Andecaliximab plus modified (m)FOLFOX6 first-line therapy for metastatic gastric adenocarcinoma did not improve study outcomes in an unselected study population, but improved efficacy was reported in patients ≥65 years of age.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
Results from a single-arm phase 2 study show ramucirumab plus irinotecan yields promising antitumor activity and safety results in patients with advanced gastric cancer.
2021 Year in Review - Gastrointestinal Cancer | December 1, 2021
The addition of neoadjuvant chemotherapy to D2 surgery plus adjuvant chemotherapy improves progression-free survival in patients with resectable locally advanced gastric cancer.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512